A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2- breast cancer Meeting Abstract
| Authors: | Jhaveri, K.; Kalinsky, K.; Bedard, P.; Cervantes, A.; Saura, C.; Krop, I.; Hamilton, E.; Schmid, P.; Varga, A.; Turner, N.; Italiano, A.; Gambardella, V.; Veitch, Z.; Oliveira, M.; Dickmann, L.; Kotani, N.; Kapp, A.; Hutchinson, K.; Royer-Joo, S.; Vaze, A.; Schutzman, J.; Juric, D. |
| Abstract Title: | A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients with PIK3CA-mutant HR+/HER2- breast cancer |
| Meeting Title: | 42nd Annual San Antonio Breast Cancer Symposium (SABCS) |
| Journal Title: | Cancer Research |
| Volume: | 80 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2019 Dec 10-14 |
| Meeting Location: | San Antonio, TX |
| ISSN: | 0008-5472 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2020-02-01 |
| Language: | English |
| ACCESSION: | WOS:000527012500363 |
| DOI: | 10.1158/1538-7445.Sabcs19-p1-19-46 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: P1-19-46 -- Source: Wos |
